GlobeNewsWire
16 Jun 2026, 21:36 UTC · 14w ago
Verdict
Headline takes no side. We score ADCT −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 94% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
ADC Therapeutics' Phase 3 LOTIS-5 trial for ZYNLONTA recorded 27 deaths in the treatment arm compared to nine in the immunotherapy arm.
More negative than 99% of claims this week
ADC Therapeutics' stock price fell approximately 66.56% over two trading sessions following the release of the LOTIS-5 data.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 95% of claims this week
Pomerantz LLP is investigating ADC Therapeutics for potential securities fraud or unlawful business practices related to these developments.
More negative than 85% of claims this week
Which stocks this story touches
More negative than 94% of ticker scores this week
The company is facing a potential class action investigation for securities fraud following a 66% stock price crash due to poor trial data.
More negative than 72% of ticker scores this week
The company is the subject of an investigation by a law firm on behalf of investors.
More negative than 72% of ticker scores this week
The company is the subject of an investigation by a law firm on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
4h ago
+26.5%
Price is moving against the score
$1.26 vs $0.9963 close before publication (Jun 16) · not market-adjusted
ADCT chart →
